Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancerJ M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2017
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung CancerA J van der Wekken, R Pelgrim, N 't Hart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 5, 2021
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancerI C Kok, J S Hooiveld, P P van de Donk, et al.
ESMO Open|November 5, 2024
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapyV D de Jager, P Plomp, M S Paats, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS studyJ W T van der Wel, S M Ernst, M Jebbink, et al.
Pageof 2